Considering the potential diagnoses of TTP or hemolytic uremic syndrome (HUS), further tests were conducted, including the gene mutation analysis for coagulopathy and hematologic malignancies, measurement of sC5b-9, complement factor I and complement factor H levels, and ADAMTS13 activity. This evidence concerns the gene CFH and hemolytic-uremic syndrome.